However, delivery of recombinant growth factors such as vascular endothelial growth factor A (VEGF-A) offered no therapeutic benefits in clinical trials for PAD, suggesting that regulation of angiogenesis goes beyond ligand-receptor interactions (7). Here, VEGFA is linked to peripheral arterial disease.